Regardless of the mechanism(s) by which CTLA‐4 regulates DC function, these data highlight this inhibitory receptor as a relevant innate checkpoint in DC that can be targeted to enhance the immunostimulatory activity of these cells in the context of cancer. Here, CTLA4 is linked to cancer.